The Food and Drug Administration (FDA) are looking into cases of loss of consciousness and abuse identified during a postmarketing review with the anti-obesity drug Contrave. Contrave was approved by the FDA September 2014. It is a combination of the alcohol and opioid dependence treatment naltrexone hydrochloride and the antidepressant bupropion hydrochloride. Contrave is intended as a treatment option for chronic weight management in obese patients (those with a BMI of 30 or greater) or overweight patients (those with a BMI of 27 or greater) who have at least one weight-related condition such as high blood pressure, type 2 diabetes, ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.